- Home
- AGIO vs IBRX Comparison
AGIO vs IBRX Comparison
Compare AGIO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- IBRX
- Stock Information
- Founded
- AGIO 2007
- IBRX 2014
- Country
- AGIO United States
- IBRX United States
- Employees
- AGIO N/A
- IBRX N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGIO Health Care
- IBRX Health Care
- Exchange
- AGIO Nasdaq
- IBRX Nasdaq
- Market Cap
- AGIO 2.4B
- IBRX 2.4B
- IPO Year
- AGIO 2013
- IBRX N/A
- Fundamental
- Price
- AGIO $35.42
- IBRX $2.62
- Analyst Decision
- AGIO Buy
- IBRX Buy
- Analyst Count
- AGIO 7
- IBRX 2
- Target Price
- AGIO $56.33
- IBRX $17.38
- AVG Volume (30 Days)
- AGIO 1.1M
- IBRX 6.1M
- Earning Date
- AGIO 02-13-2025
- IBRX 11-12-2024
- Dividend Yield
- AGIO N/A
- IBRX N/A
- EPS Growth
- AGIO N/A
- IBRX N/A
- EPS
- AGIO 11.80
- IBRX N/A
- Revenue
- AGIO $32,871,000.00
- IBRX $7,332,000.00
- Revenue This Year
- AGIO $33.38
- IBRX $2,572.99
- Revenue Next Year
- AGIO $163.06
- IBRX $747.59
- P/E Ratio
- AGIO $3.00
- IBRX N/A
- Revenue Growth
- AGIO 36.79
- IBRX 1218.71
- 52 Week Low
- AGIO $20.96
- IBRX $2.61
- 52 Week High
- AGIO $62.58
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- AGIO 28.75
- IBRX 28.04
- Support Level
- AGIO $37.20
- IBRX $2.61
- Resistance Level
- AGIO $44.46
- IBRX $3.18
- Average True Range (ATR)
- AGIO 4.27
- IBRX 0.28
- MACD
- AGIO -2.06
- IBRX -0.20
- Stochastic Oscillator
- AGIO 1.06
- IBRX 0.40
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.